Artiva Biotherapeutics, Inc.
http://www.artivabio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Artiva Biotherapeutics, Inc.
Korean Pharmas Race To Globalize But Tacks Vary
Although South Korean pharma firms are largely sailing toward the common goal of globalization, they have different strategies to reach their goals. Scrip takes a look at the variety of paths being pursued.
Merck & Co. Looks To Artiva’s Off-The-Shelf Cell Therapy Technologies
Deal Snapshot: Pharma places $30m upfront wager on biotech’s allogeneic natural killer cell and chimeric antigen receptor technologies, with hopes for solid tumor cell therapies.
GC LabCell Taps Alliances In Bid For Lead NK Cell Position
After accumulating technologies to develop off-the-shelf, allogeneic NK cell therapies over the past decade, Korea's GC LabCell is now tapping into the global market as US partner Artiva begins clinical trials of its lead asset.
Deal Watch: Affimed Teams Up In Immuno-Oncology With Roivant, Artiva
German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.
Company Information
- Industry
- Biotechnology
-
Biotechnology
- Gene Therapy, Cell Therapy